Showing 2991-3000 of 4166 results for "".
- Clearside Biomedical Announces Multiple Poster Presentations at ARVOhttps://modernod.com/news/clearside-biomedical-announces-multiple-poster-presentations-at-arvo/2479185/Clearside Biomedical announced that multiple clinical poster presentations related to its suprachoroidal injection platform and programs were delivered at the Association for Research in Vision and Ophthalmology 2021 Virtual Meeting which took place May 1-7, 2021.
- Tarsus Pharmaceuticals Presents Results of Atlas Study Demonstrating the Functional and Psychosocial Impact of Demodex Blepharitishttps://modernod.com/news/tarsus-pharmaceuticals-presents-results-of-atlas-study-demonstrating-the-functional-and-psychosocial-impact-of-demodex-blepharitis/2479161/Tarsus Pharmaceuticals announced data from its Demodex blepharitis clinical program presented at the virtual Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting. Tarsus’ lead product candidate, TP-03, is a topical ophthalmic formulation of lotilaner, a well-characteriz
- jCyte Identifies Predictive Biomarker for jCell Therapy in Largest Phase 3 Study for Retinitis Pigmentosahttps://modernod.com/news/jcyte-identifies-predictive-biomarker-for-jcell-therapy-in-largest-phase-3-study-for-retinitis-pigmentosa/2479157/jCyte announced presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting, identifying a predictive biomarker for the upcoming phase 3 study for jCell therapy in retinitis pigmentosa. A detailed analysis by the Cleveland Clinic Cole Eye Institute
- Bausch + Lomb Will Present New Scientific Data And Analyses On Products And Pipeline Programs During ARVO 2021https://modernod.com/news/bausch-lomb-will-present-new-scientific-data-and-analyses-on-products-and-pipeline-programs-during-arvo-2021/2479139/Bausch + Lomb announced the presentation of new scientific data and clinical analyses, including one podium presentation and 11 poster presentations, during the virtual Association for Research in Vision and Ophthalmology (ARVO) annual meeting, which will take place from Ma
- Essilor to Present New Results for its Stellest Lens for Children With Myopiahttps://modernod.com/news/essilor-to-present-new-results-for-its-stellest-lens-for-children-with-myopia/2479062/Essilor will unveil pivotal 2-year clinical trial results of its Stellest lens for myopia. The 2-year results demonstrate that Essilor Stellest lenses slow down myopia progression by 67% on average, when compared to single vision lenses, when worn at least 12 hours a day,1 according to
- Center For Sight is the First Practice Worldwide to Offer the OptiBlue IOLhttps://modernod.com/news/center-for-sight-is-the-first-practice-worldwide-to-offer-the-optiblue-iol/2478793/Center For Sight, which operates 14 eye clinics and surgery centers in Southwest Florida, is the first eye care practice to offer the new OptiBlue IOLs (Johnson & Johnson Vision), an advanced intraocular lens technology that filters violet light to improve contrast and clarity for cataract pa
- Tilak Healthcare Partners With Novartis to Promote Mobile App OdySighthttps://modernod.com/news/tilak-healthcare-partners-with-novartis-in-ophthalmology/2478634/Tilak Healthcare, a provider of digital therapeutics, has announced an agreement with Novartis Pharma for the promotion internationally of OdySight, Tilak Healthcare’s first clinically validated mobile app for patient remote vision monitoring. Financial terms of the deal were not disclosed
- Study: Essilor’s Stellest Lens Slows Down Myopia Progression in Children by More Than 60% After One Yearhttps://modernod.com/news/study-essilors-stellest-lens-slows-down-myopia-progression-in-children-by-more-than-60-after-one-year/2478339/Essilor reported that after 1 year of an ongoing clinical trial, there was a more than 60% slowdown in myopia progression in children on average with the recently launched Stellest lens, compared to a single vision lenses. Essilor launched the Stellest lens in the Wenzhou Medical Universit
- Physician-Scientists Pioneer New Surgical Approach to Treat Progressive Blindnesshttps://modernod.com/news/physician-scientists-pioneer-new-surgical-approach-to-treat-progressive-blindness/2477568/Dry age-related macular degeneration (AMD) poses a significant clinical challenge. It is one of the leading causes of progressive blindness, robbing millions of people over the age of 65 of their central vision, and it often hinders patients’ abilities to read books, drive and discern the faces o
- Study: Eye Damage Linked to Over-the-Counter Vitamin That Lowers Cholesterol Can Be Reversedhttps://modernod.com/news/study-eye-damage-linked-to-over-the-counter-vitamin-that-lowers-cholesterol-can-be-reversed/2477051/In a first-of-its-kind clinical report, retina specialists at the New York Eye and Ear Infirmary of Mount Sinai (NYEE) have shown that severe vision loss from a self-prescribed high dose of over-the-counter niacin is linked to injury of a specific cell type in a patient’s eye. The experts report